US pivotal trial is a multi-center study evaluating a bioabsorbable hemodialysis vascular access implant across complex ...
The MarketWatch News Department was not involved in the creation of this content. Xeltis secures nearly EUR50m from the European Investment Bank (EIB) and existing shareholders to advance aXess, its ...
Xeltis Completed Second Feasibility Clinical Trial on Bioabsorbable Cardiovascular Device Technology
Xeltis developing first cardiac valves and vessels designed to allow endogenous tissue restoration The Xeltis products are made of bioabsorbable polymers structured as a porous matrix that is designed ...
The EU study aims to assess the Xabg technology in patients with multi-vessel atherosclerotic coronary artery disease who are scheduled for elective CABG surgery. Credit: Photoroyalty / ...
Xeltis, a clinical-stage medical device company pioneering a restorative approach in heart valve therapy, today announced the completion of an oversubscribed €45 million ($52 million) Series C ...
The MarketWatch News Department was not involved in the creation of this content. -- CE mark awarded for aXess(TM) at record speed, underpinned by strong EU pivotal trial data -- Xeltis advances ahead ...
A pioneering approach to heart valve therapy from Swiss-Dutch clinical stage company Xeltis was the focus of plenary session "Bioresorbable valve therapy: tomorrow's world" at EuroPCR 2017 in Paris ...
EINDHOVEN, The Netherlands, July 02, 2026 (GLOBE NEWSWIRE) -- Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results